Paclitaxel combined with hyarulonic acid as the new drug for peritoneal dissemination of gastric cancer.
Project/Area Number |
20591563
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | The University of Tokyo |
Principal Investigator |
KITAYAMA Joji (2009-2010) The University of Tokyo, 医学部附属病院, 准教授 (20251308)
秀村 晃生 (2008) The University of Tokyo, 医学部附属病院, 助教 (70401099)
|
Co-Investigator(Kenkyū-buntansha) |
ISHIGAMI Hironori 東京大学, 医学部附属病院, 講師 (80372382)
北山 丈二 東京大学, 医学部・附属病院, 准教授 (20251308)
|
Co-Investigator(Renkei-kenkyūsha) |
HIDEMURA Akio 東京大学, 医学部附属病院, 助教 (70401099)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 腹膜播種 / 腹腔内化学療法 / パクリタキセル / シスプラチン / NASHA / 腹腔内投与 / PMB30W / 胃癌 / ヒアルロン酸 |
Research Abstract |
Intraperitoneal chemotherapy has been shown to be clinically useful for peritoneal matastais. In this study, we hypothesized that high molecular weight Hyarulonic Acid may retain the intraperitoneally administrated anticancer drugs in abdominal cavity and enhance the anti-tumor effects, and examined the effect of Non-Animal Stabilized Hyarulonic Acid (NASHA) (Q-Med Sweden). In fact, the addition of 5% NASHA suppressed the development of peritoneal nodules of MKN45 inplanted in nude mice significantly greater than paclitaxel or cisplatin alone. NASHA also increased the volume of fluid recovered from the mice. Intraperitoneal administration paclitaxel or cisplatin combined with NASHA can be a hopeful strategy as the treatment of peritoneal dissemination.
|
Report
(4 results)
Research Products
(15 results)
-
-
-
[Journal Article] Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.2010
Author(s)
Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H
-
Journal Title
Oncology. 78(1)
Pages: 40-6
Related Report
Peer Reviewed
-
-
-
-
-
-
[Journal Article] Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer.2008
Author(s)
Yamada J, Kitayama J, Tsuno NH, Yamashita H, Miyato H, Soma D, Otani K, Kamei T, Ishigami H, Hidemura A, Kaisaki S, Takahashi K, Nagawa H
-
Journal Title
Cancer Lett. 272(2)
Pages: 307-15
Related Report
Peer Reviewed
-
-
-
-
-
-